Friday, June 2, 2023; 2:45 PM–5:45 PM CDT
Oral Abstract Session
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

4000 ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer. M Terashima, Y-K Kang, YW Kim, et al

Take-Home Message

• The results of an immune checkpoint inhibitor (nivolumab) in combination with adjuvant chemotherapy in the treatment of pathological stage III gastric or gastroesophageal junction (G/GEJ) cancer are reported. The study was conducted in Japan, China, Korea, and Taiwan. Participants had undergone D2 or more extensive gastrectomy and were randomized to nivolumab/chemotherapy or to placebo/chemotherapy.
• The study did not meet its primary efficacy endpoint of centrally assessed relapse-free survival, with 3-year relapse-free rates of 68.4% in the nivolumab arm and 65.3% in the placebo arm. Grade≥3 treatment-associated adverse events were 54.4% in the nivolumab arm and 46.8% in the placebo arm.

4100 Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. S Yuan, R-C Nie, Y Jin, et al

Take-Home Message

• This prospective randomized phase II trial was designed to evaluate the effectiveness of adding the PD-1 antibody toripalimab to perioperative chemotherapy in patients with locally advanced resectable gastric or GEJ cancer. In total, 108 participants were enrolled and assessed using an intention-to-treat analysis. The toripalimab plus chemotherapy arm achieved a higher proportion of pathological complete regression/moderate regression rate (the primary endpoint) compared with the chemotherapy alone arm. The pathological response rate was higher (24.1%) in the toripalimab arm than in the chemotherapy arm (9.3%). Rates of surgical morbidity and mortality were comparable between the arms, as were rates of treatment-related adverse events.
• The results suggest that perioperative toripalimab plus chemotherapy may be an option for patients with locally advanced resectable gastric or GEJ cancer.

Monday, June 5, 2023; 11:30 AM–1:00 PM CDT
Poster Discussion Session
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

4014 KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations. SY Rha, L Wyrwicz, PEY Weber, et al

4027 A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA). SJ Klempner, BB Sonbol, ZA Wainberg, et al

ASCO 2023, spijsverteringskanker, aanbevolen abstracten, darmkanker, slokdarmkanker, rectumkanker, maagkanker

---

• ASCO 2023: aanbevolen abstracten gerelateerd aan spijsverteringskanker waaronder vormen van darmkanker en maagkanker door vooraanstaande medisch specialisten

---

• ASCO 2020: aanbevolen abstracten voor vormen van spijsverteringskanker waaronder darmkanker en maagkanker

---

• Aanbevolen abstracten voor vormen van spijsverteringskanker waaronder alvleesklierkanker, darmkanker en maagkanker van ASCO 2019

---

• ASCO 2024: aanbevolen abstracten gerelateerd aan spijsverteringskanker waaronder darmkanker en maagkanker door oncologen wereldwijd